ATMA Welcomes Dr. Scott Shannon, MAPS MDMA Phase 3 Principal Investigator, to Expand Its’ Clinical Training Expertise in MDMA-Assisted Therapy
CALGARY, October 24, 2023 – ATMA Journey Centers Inc. (“ATMA”), a Canadian company with a primary focus on advancing psychedelic-assisted therapy, is […]
Read more
